The research, conducted by scientists from the China Academy of Chinese Medical Sciences and Fujian University of Traditional Chinese Medicine, addresses a major challenge in liver cancer treatment. Hepatocellular carcinoma often develops in the context of chronic liver disease and can be difficult to control once it has progressed. Although surgery, ablation, immunotherapy, targeted drugs, and chemotherapy can benefit selected patients, treatment resistance and disease recurrence remain widespread. Artesunate is already widely used against malaria, giving it an established pharmacological history and a well-characterized clinical profile. However, the molecular basis of its activity against cancer has remained incompletely understood.

The investigators first examined how artesunate affected the survival and growth of two human hepatocellular carcinoma cell lines, HepG2 and MHCC-97H. Using the CCK8 assay, which measures cellular metabolic activity as an indicator of viability and proliferation, they found that artesunate inhibited both cell lines in a concentration-dependent manner. HepG2 cells were more sensitive than MHCC-97H cells, suggesting that differences in metabolic state or drug-response pathways may influence the treatment’s effectiveness. Additional experiments showed that artesunate reduced cancer-cell proliferation and increased the proportion of cells undergoing apoptosis, a tightly regulated form of cell death that is frequently disabled in tumors.

The study also examined artesunate in an orthotopic mouse model, in which HepG2 cells were injected into the liver to reproduce a more realistic tumor environment than conventional subcutaneous models. Animals receiving low, middle, or high doses of artesunate showed evidence of increased tumor-cell apoptosis. TUNEL staining, which detects fragmented DNA associated with programmed cell death, and Hoechst staining, which reveals changes in nuclear structure, both supported the conclusion that artesunate promoted apoptosis in the tumors. The effects were compared with control animals and with a group receiving 5-fluorouracil, a commonly used anticancer drug. These experiments provided in vivo support for the cellular findings, although additional animal and clinical studies will be necessary to determine whether the effect can be translated into a useful treatment.

The researchers connected artesunate’s activity to sphingolipid metabolism, a biochemical network that produces and regulates lipids involved in membrane structure, cell signaling, inflammation, and cell death. GBA normally helps break down glucosylceramide, a glycosphingolipid, into downstream metabolic products. When GBA was inhibited by artesunate, glucosylceramide-related metabolites accumulated and the balance of cellular sphingolipids was disturbed. Such metabolic changes can place stress on organelles and alter signaling pathways that control survival. In the treated liver cancer cells, this disruption was associated with mitochondrial dysfunction, a critical event because mitochondria regulate the intrinsic pathway of apoptosis.

The study describes a signaling sequence linking altered lipid metabolism to mitochondrial apoptosis: GBA, ceramide, cathepsin D, alpha-synuclein, BID, and BAX. In this proposed GBA–ceramide–CTSD–α-syn–BID–BAX axis, artesunate first suppresses GBA activity, altering ceramide metabolism. The resulting biochemical imbalance interferes with the maturation or function of cathepsin D, a lysosomal protease. It also promotes the accumulation of alpha-synuclein, a protein better known for its association with neurodegenerative disease but increasingly recognized as a regulator of cellular stress and organelle communication. These changes facilitate cleavage of BID and increase the activity or abundance of BAX, two important components of the mitochondrial death pathway. BAX can promote mitochondrial membrane permeabilization, allowing apoptotic factors to escape and activate downstream caspases, the enzymes that dismantle the cell.

Rescue experiments strengthened the proposed mechanism. When researchers supplemented cells with ceramide, they were able to influence the apoptotic response, supporting the idea that sphingolipid imbalance lies between GBA inhibition and mitochondrial damage. Conversely, suppressing alpha-synuclein reduced key effects of artesunate, indicating that alpha-synuclein accumulation is not simply a passive consequence of treatment but contributes to the death signal. The researchers also tested LTI-291, described in the study as a GBA enzyme activator, in combination with high-dose artesunate. The combined treatment helped probe whether restoring GBA-related activity could counteract artesunate’s effects. Together, these interventions provided functional evidence that the pathway is central to the drug’s anticancer action rather than being an incidental molecular signature.

A particularly significant part of the work focused on the physical interaction between artesunate and GBA. Through computational modeling and biochemical analyses, the researchers identified three amino-acid residues—tyrosine 313, glutamate 340, and asparagine 396—as important potential contact points within the enzyme’s active site. Site-directed mutagenesis was then used to replace selected residues and test their importance experimentally. Mutations affecting E340 and N396 substantially weakened artesunate binding and reduced GBA enzymatic activity. The altered enzyme also lost much of its ability to transmit the downstream apoptotic response induced by artesunate. These results support a direct target-engagement model in which the drug’s chemical structure fits into a functional region of GBA and changes the enzyme’s behavior.

The findings are notable because they move beyond the observation that artesunate can kill cancer cells and begin to explain why. Drug repurposing often starts with a promising biological effect, but successful development requires knowledge of the target, the binding site, the responsive cancer subtypes, and the mechanisms that may produce resistance. By defining GBA as a direct molecular target and connecting it to a lipid-regulated apoptotic pathway, the study offers several possible directions for future research. GBA expression or sphingolipid profiles might eventually help identify tumors most likely to respond, while combinations involving ceramide metabolism, lysosomal function, or mitochondrial apoptosis could potentially improve treatment activity.

At the same time, the results should not be interpreted as evidence that artesunate is already an established liver cancer therapy. The experiments were performed mainly in cultured cell lines and mouse models, systems that cannot fully reproduce the genetic diversity, immune environment, drug metabolism, and treatment history of human tumors. The greater sensitivity of HepG2 cells compared with MHCC-97H cells also highlights the possibility that response depends on tumor-specific biology. Future work will need to test the mechanism in patient-derived organoids, genetically diverse xenograft models, and carefully designed pharmacological studies. Long-term safety, optimal dosing, interactions with current liver cancer treatments, and the effects of artesunate on healthy liver tissue will also require detailed evaluation.

Published in Genes & Diseases, the study presents artesunate as more than an antimalarial compound with broad anticancer activity. It identifies a defined enzyme target, maps critical binding residues, and traces a mechanistic route from altered sphingolipid metabolism to mitochondrial apoptosis in hepatocellular carcinoma. If the findings are confirmed in clinically relevant models and human studies, GBA-targeted strategies could expand the therapeutic possibilities for a cancer that continues to demand more effective and durable treatments. For now, the work provides a compelling molecular blueprint for investigating how an established medicine might be redesigned or repurposed to exploit metabolic weaknesses in liver cancer.

Subject of Research: Artesunate-induced apoptosis and GBA-targeted mechanisms in hepatocellular carcinoma

Article Title: Artesunate directly targets glucosylceramidase to suppress hepatocellular carcinoma proliferation and trigger apoptosis

Web References: https://doi.org/10.1016/j.gendis.2026.102045; https://www.sciencedirect.com/journal/genes-and-diseases

References: Genes & Diseases, DOI: 10.1016/j.gendis.2026.102045

Image Credits: Xia Mao, Xiangying Yan, Yawen Chen, Bingbing Cai, Wenjia Chen, Ya Lin, Na Lin, Yanqiong Zhang

Keywords

Artesunate, hepatocellular carcinoma, liver cancer, glucosylceramidase, GBA, sphingolipid metabolism, ceramide, mitochondrial apoptosis, cathepsin D, alpha-synuclein, BID, BAX, drug repurposing

Hepatocellular carcinoma remains a formidable clinical challenge, largely due to its late diagnosis and resistance to conventional therapies. Existing treatments, including surgical resection, locoregional therapies, and systemic agents, often fall short in delivering long-term survival benefits for many patients. The study’s focus on ChaC1, a known regulator of intracellular stress responses, capitalizes on the growing understanding that cancer cells rely heavily on proteostasis mechanisms to survive hostile tumor microenvironments. By targeting these delicate cellular processes, the research team aimed to disrupt the cancer’s adaptive capabilities, thereby inducing cell death selectively in malignant hepatocytes.

The researchers employed an innovative ChaC1-based screening platform, designed to identify compounds that modify the activity of this critical proteostasis effector. ChaC1 is implicated in regulating glutathione metabolism and redox balance, processes intricately linked to cellular oxidative stress management. Intriguingly, alterations in these pathways have been strongly associated with cancer cell survival and drug resistance. By leveraging this biochemical node as a screening target, the team succeeded in uncovering compounds that exerted augmented cytotoxic effects in HCC models.

Auranofin, a gold-containing compound with a long history of use in rheumatoid arthritis, emerged from the screens as a potent modulator of ChaC1 activity. Importantly, auranofin’s inhibition of thioredoxin reductase disrupts cellular antioxidant defenses, heightening oxidative stress—a vulnerability exploited by combining it with proteasome inhibitors. Proteasome inhibition is a therapeutic approach that hinders the degradation of misfolded or damaged proteins, leading to proteotoxic stress that cancer cells are particularly sensitive to. The synergistic effect of these two agents triggers an overwhelming accumulation of toxic protein aggregates and reactive oxygen species, compelling cancer cells towards apoptosis.

In vitro experiments conducted across various hepatocellular carcinoma cell lines demonstrated a dramatic reduction in cell viability when treated with the combined regimen of auranofin and proteasome inhibitors, compared to either agent alone. This finding underscores the therapeutic potential of capitalizing on dual vulnerabilities in the cellular protein quality control machinery. The study further delved into mechanistic analyses revealing that ChaC1 modulation aggravates oxidative and proteotoxic stress, effectively pushing tumor cells beyond their survival threshold.

Another intriguing aspect of the research pertains to the selective toxicity profile of the drug combination. While cancer cells exhibited pronounced susceptibility to the dual treatment, non-malignant hepatocytes were largely spared, suggesting a possible therapeutic window that could minimize collateral damage in normal tissue. This selectivity is paramount in cancer treatment development, where minimizing adverse effects remains a critical hurdle in clinical application.

The clinical implications of this discovery could be profound. Given that both auranofin and proteasome inhibitors such as bortezomib and carfilzomib are already FDA-approved agents, repurposing these drugs for HCC treatment could significantly shorten the timeline from bench to bedside. The use of clinically validated compounds also facilitates the design of combination therapy trials, as known pharmacokinetics and safety profiles can expedite regulatory approvals and patient enrollment.

Moreover, the identification of ChaC1 as a predictive biomarker for therapeutic responsiveness opens the door to more personalized medicine approaches in oncology. Patients with elevated ChaC1 expression or activity in their tumors might be stratified to receive this combinatorial treatment, enhancing efficacy and sparing non-responders from unnecessary toxicity. Future studies aimed at validating these biomarkers in clinical cohorts will be indispensable for translating the preclinical findings into routine clinical practice.

The research also raises exciting possibilities for investigating similar synergistic drug combinations in other cancers where proteostasis disruption is a hallmark, broadening the impact beyond hepatocellular carcinoma. Such cross-cancer applicability would underscore the universal importance of cellular stress response pathways in malignancy and cancer therapy.

From a molecular biology perspective, this study deepens our understanding of how redox regulation and protein degradation pathways converge to control cancer cell survival. It provides compelling evidence that targeting these interconnected cellular stress responses can deliver powerful anti-tumor effects. This aligns with emerging trends in oncology that emphasize combinational strategies over single-agent treatments for overcoming resistance and enhancing therapeutic durability.

In summary, Yu et al.’s work represents a significant advancement in the fight against hepatocellular carcinoma. By ingeniously leveraging ChaC1’s role in cellular stress response, they have uncovered a synergistic lethal interaction between auranofin and proteasome inhibitors. This discovery not only points to an innovative treatment strategy but also exemplifies the power of targeted, mechanism-based drug screening in oncology drug development. As follow-up in vivo studies and clinical trials advance, the oncology community awaits with anticipation the potential of these findings to improve outcomes for patients afflicted with this devastating disease.

This study’s multidisciplinary methodology, integrating molecular screening, pharmacology, and functional cell biology, serves as a paradigm for future drug discovery endeavors. The promising results encourage further exploration of proteostasis and oxidative stress networks as fertile ground for next-generation cancer therapies. With continuous advancements in biomarker-guided treatment and drug combination strategies, the dawn of more effective, less toxic cancer therapeutics appears within reach.

Given the urgent need to develop better therapies for hepatocellular carcinoma, the identification of this novel drug synergy brings hope to patients and clinicians alike. It also exemplifies the remarkable potential of repurposing existing drugs in innovative ways, a cost-effective and efficient path toward addressing unmet clinical needs. As our molecular toolkit and understanding of cancer complexities evolve, studies like this pave the pathway to transformative breakthroughs that could redefine clinical oncology in the near future.

Subject of Research: Hepatocellular carcinoma treatment and ChaC1-mediated cellular stress pathways.

Article Title: ChaC1-based drug screenings identify a synergistic lethal effect of auranofin and proteasome inhibitors in hepatocellular carcinoma cells.

Article References:
Yu, C., Liu, J., Jian, H. et al. ChaC1-based drug screenings identify a synergistic lethal effect of auranofin and proteasome inhibitors in hepatocellular carcinoma cells. Cell Death Discov. 11, 532 (2025). https://doi.org/10.1038/s41420-025-02838-6

Image Credits: AI Generated

DOI: 17 November 2025